Трансплантация генетически модифицированных стволовых клеток, повышенно экспрессирующих терапевтические ростовые факторы, при лечении экспериментального инфаркта миокарда крыс

Автор: Коноплянников Михаил Анатольевич, Хайдер Х.Х., Ашраф М.

Журнал: Клиническая практика @clinpractice

Статья в выпуске: 3 (15), 2013 года.

Бесплатный доступ

Мы проанализировали гипотезу, что одновременная трансгенная модификация трансплантируемых стволовых клеток 4-мя ростовыми факторами активирует разнообразные сигнальные механизмы для выживания введенных клеток, а также мобилизацию различных стволовых/прогениторных клеток для кардиогенеза при терапии инфаркта миокарда. Плазмиды, несущие гены, кодирующие IGF-1, VEGF, SDF-1α и HGF, были сконструированы и трансфицированы в скелетные миобласты (SM) крыс. Повышенная экспрессия ряда факторов в трансфицированных SM (TransSM) была подтверждена методами ПЦР, Вестерн-блоттинга (ВБ) и иммунофлюоресцентного окрашивания. Кондиционная среда от TransSM обладала цитопротекторными свойствами для кардиомиоцитов в условиях окислительного стресса, стимулировала миграцию клеток HUVEC, и усиливала ангиогенез клеток HUVEC in vitro. Интрамиокардиальная трансплантация 1,5×106 TransSM продемонстрировала обширную мобилизацию стволовых/прогениторных клеток в инфарктном миокарде и улучшала интегрирование TransSM в сердце. Экстенсивный неомиогенез и ангиогенез наблюдался через8 недель после трансплантации. Итак, одновременная активация разнообразных сигнальных механизмов благодаря повышенной экспрессии нескольких ростовых факторов вызывает массовую мобилизацию и хоминг как стволовых/прогениторных клеток из костного мозга и циркулирующих в крови, так и резидентных кардиальных стволовых клеток, что приводит к ускоренной репарации инфарктного миокарда.

Еще

Стволовые клетки, инфаркт миокарда, трансгенная модификация, трансплантация клеток, сердечно-сосудистая регенерация, паракринные факторы

Короткий адрес: https://sciup.org/14338459

IDR: 14338459

Список литературы Трансплантация генетически модифицированных стволовых клеток, повышенно экспрессирующих терапевтические ростовые факторы, при лечении экспериментального инфаркта миокарда крыс

Singla DK. Stem cells in the infarcted heart. J Cardiovasc Transl Res 2010; 3:73-78.
P Menasche, A A Hagege, M Scorsin, B Pouzet, M Desnos, et al. Myoblast transplantation for heart failure. Lancet 2001;357: 279-280.
P Menasche, O Alfieri, S Janssens, W McKenna, H Reichenspurner, L Trinquart, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008; 117:1189-1200.
KC Wollert, GP Meyer, J Lotz, S Ringes-Lichtenberg, P Lippolt, C Breidenbach, S Fichtner, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004;364:141-148.
BZ Atkins, MT Hueman, J Meuchel, KA Hutcheson, et al. Cellular cardiomyoplasty improves diastolic properties of injured heart. J Surg Res 1999; 85:234-242.
DA Taylor, BZ Atkins, P Hungspreugs, TR Jones, MC Reedy, KA Hutcheson, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998; 4: 929-933.
M Perez-Ilzarbe, O Agbulut, B Pelacho, C Ciorba, E San JoseEneriz, M Desnos, AA Hagege, P Aranda, EJ Andreu, P Menasche and F Prosper. Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. Eur J Heart Fail 2008;10:1065-1072.
J Kajstura, M Rota, B Whang, S Cascapera, T Hosoda, C Bearzi, D Nurzynska, H Kasahara, E Zias, et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ Res 2005;96:127-137.
R Uemura, M Xu, N Ahmad and M Ashraf. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res 2006;98: 1414-1421.
K Jujo, M Ii and DW Losordo. EPC in neovascularization of infarcted myocardium. J Mol Cell Cardiol 2008;45: 530-544.
B Dawn, AB Stein, K Urbanek, M Rota, B Whang, R Rastaldo, D Torella, XL Tang, A Rezazadeh, et al. Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function. Proc Natl Acad Sci USA 2005;102:3766-3771.
M Rota, ME Padin-Iruegas, Y Misao, A De Angelis, S Maestroni, J Ferreira-Martins, E Fiumana, R Rastaldo, ML Arcarese, et al. Local activation or implantation of cardiac progenitor cells rescues scarred infarcted myocardium improving cardiac function. Circ Res 2008;103:107-116.
A Banfi, ML Springer,HM Blau. Myoblast-mediated gene transfer for therapeutic angiogenesis. Methods Enzymol 2002;346:145-157.
MI Niagara, H Haider, S Jiang, M Ashraf. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 2007;100:545-555.
M Konoplyannikov, Haider KH, Lai VK, Ahmed RP, Jiang S, Ashraf M. Activation of diverse signaling pathways by ex-vivo delivery of multiple cytokines for myocardial repair. Stem Cells Dev 2013. Jan 15; 22(2): 204-15.
MA Stagg, SR Coppen, K Suzuki, A Varela-Carver, J Lee, NJ Brand, S Fukushima, MH Yacoub, CM Terracciano. Evaluation of frequency, type, and function of gap junctions between skeletal myoblasts overexpressing connexin43 and cardiomyocytes: relevance to cell transplantation. Faseb J 2006; 20:744-746.
Jiang S, H Haider, NM Idris, A Salim, M Ashraf. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 2006; 99:776-784.
G Lu, HK Haider, S Jiang and M Ashraf. Sca-1+ stem cell survival and engraftment in the infarcted heart: dual role for preconditioning-induced connexin. Circulation 2009;119: 2587-96.
HW Kim, HK Haider, S Jiang and M Ashraf. Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 2009; 284: 33161-168.
JY Hahn, HJ Cho, HJ Kang, TS Kim, MH Kim, JH Chung, JW Bae, BH Oh, YB Park and HS Kim. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap-junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 2008; 51: 933-43.
KM Sutton, S Hayat, NM Chau, S Cook, J Pouyssegur, A Ahmed, N Perusinghe, et al. Selective inhibition of MEK1/2 reveals a differential requirement for ERK1/2 signalling in the regulation of HIF-1 in response to hypoxia and IGF-1. Oncogene 2007; 26: 3920-29.
M Pedersen, T Lofstedt, J Sun, L Holmquist-Mengelbier, S Pahlman, L Ronnstrand. Stem cell factor induces HIF-1α at normoxia in hematopoietic cells. Biochem Biophys Res Commun 2008; 377: 98-103.
N Ferrara, HP Gerber, J LeCouter. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
HP Gerber, AK Malik, GP Solar, D Sherman, XH Xiang, G Meng, K Hong, JC Marsters, N Ferrara. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-58.
RJ Lee, ML Springer, WE Blanco-Bose, R Shaw, PC Ursell, HM Blau. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102: 898-901.
A Linke, P Muller, D Nurzynska, C Casarsa, D Torella, A Nascimbene, et al. Stem cells in the dog heart are self-renewing, clonogenic, and multipotent and regenerate infarcted myocardium, improving cardiac function. Proc Natl Acad Sci USA 2005; 102: 8966-71.
R Madonna, G Rokosh, R De Caterina, R Bolli. Hepatocyte growth factor/Met gene transfer in cardiac stem cells-potential for cardiac repair. Basic Res Cardiol 2010; 105: 443-52.
K Tambara, GU Premaratne, G Sakaguchi, N Kanemitsu, X Lin, H Nakajima, et al. Administration of control-released hepatocyte growth factor enhances the efficacy of skeletal myoblast transplantation in rat infarcted hearts by greatly increasing both quantity and quality of the graft. Circulation 2005;112: I129-34.
M Iwasaki, Y Adachi, T Nishiue, K Minamino, Y Suzuki, Y Zhang, et al. Hepatocyte growth factor delivered by ultrasound-mediated destruction of microbubbles induces proliferation of cardiomyocytes and amelioration of left ventricular contractile function in Doxorubicin-induced cardiomyopathy. Stem Cells 2005; 23: 1589-97.
A Poppe, P Golsong, B Blumenthal, R von Wattenwyl, P Blanke, F Beyersdorf, C Schlensak, M Siepe. Hepatocyte growth factor-transfected skeletal myoblasts to limit the development of post-infarction heart failure. Artif Organs 2011; 36: 238-46.
AT Askari, S Unzek, ZB Popovic, CK Goldman, F Forudi, M Kiedrowski, A Rovner, SG Ellis, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003; 362: 697-703.
M Grunewald, I Avraham, Y Dor, E Bachar-Lustig, A Itin, S Jung, S Chimenti, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory Cells. Cell 2006; 124:175-189.
S Aharinejad, D Abraham, P Paulus, K Zins, M Hofmann, W Michlits, et al. Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation. Cardiovasc Res 2008; 79: 395-404.
M Bialas, Krupka M,Janeczek A, Rozwadowska N, et al. Transient and stable transfections of mouse myoblasts with genes coding for pro-angiogenic factors. J Physiol Pharmacol 2011; 6: 219-28.
B Blumenthal, P Golsong, A Poppe, C Heilmann, C Schlensak, F Beyersdorf, M Siepe. Polyurethane scaf-folds seeded with genetically engineered skeletal myoblasts: a promising tool to regenerate myocardial function. Artif Organs 2011; 34: E46-E54.
B Heissig, K Hattori, S Dias, M Friedrich, B Ferris, NR Hackett, RG Crystal, et al. Recruitment of stem and progenitor Cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002; 109: 625-37.
Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998; 8: 171-77.
Steve E, Jones CJ. Secreted frizzled-related proteins: searching for relationships and patterns. Bio Essays 2002; 24: 811-20.
M Mirotsou, Z Zhang, A Deb, L Zhang, M Gnecchi, N Noiseux, H Mu, A Pachori, V Dzau. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci USA 2007; 104: 1643-48.
Z Zhang, A Deb, A Pachori, W He, J Guo, et al. Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. J Mol Cell Cardiol 2009; 46: 370-77.
W He, L Zhang, A Ni, Z Zhang, M Mirotsou, et al. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci USA 2010; 107: 21110-15.
H Laeremans, TM Hackeng, MA van Zandvoort, VL Thijssen, BJ Janssen, HC Ottenheijm, et al. Blocking of frizzled signaling with a homologous peptide fragment of Wnt3a/Wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation 2011;124:1626-35.
L Formigli, F Francini, A Tani, R Squecco, D Nosi, L Polidori, S Nistri, L Chiappini, V Cesati, et al. Morphofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture is favored by direct cell-cell contacts and relaxin treatment. Am J Physiol Cell Physiol 2005; 288: C795-C804.
H Reinecke, E Minami, V Poppa and CE Murry. Evidence for fusion between cardiac and skeletal muscle cells. Circ Res 2004; 94: e56-e60.

Еще

Статья научная